The shifting role of cell therapy and steroids in the relapsed/refractory setting
A conversation with Marcelo Pasquini, MD
Discussing research into improving CAR T-cell therapy efficacy
Highly personalized treatment shrinks tumors resistant to immunotherapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Findings from large database important to inform clinical practice
Higher type 2 immunity observed in persistent CAR T cells
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
Driving advances in cancer care
Advertisement
Advertisement